Home

Horník Bungalov Abecední pořadí overall response rate or drážka Opuštěný Diskriminovat

Overall Response Rate of 76% in Advanced Melanoma Patients
Overall Response Rate of 76% in Advanced Melanoma Patients

Efficacy | BALVERSA® (erdafitinib) HCP
Efficacy | BALVERSA® (erdafitinib) HCP

Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

Overall response rate | Download Table
Overall response rate | Download Table

Forest plot of the comparison of overall response rate (ORR).
Forest plot of the comparison of overall response rate (ORR).

Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP

Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire

Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review - ScienceDirect
Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review - ScienceDirect

Tumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM
Tumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM

CAR T-cell therapy shows 'high and durable response rates' in adults with B-cell ALL
CAR T-cell therapy shows 'high and durable response rates' in adults with B-cell ALL

PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar

Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies

Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know

Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know

BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC

TECARTUS® Efficacy - Response Data for R/R MCL
TECARTUS® Efficacy - Response Data for R/R MCL

Frontiers | Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
Frontiers | Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer

ODOMZO® (sonidegib) | Efficacy Data
ODOMZO® (sonidegib) | Efficacy Data

Cancers | Free Full-Text | Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
Cancers | Free Full-Text | Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

ORR (Objective Response Rate) and related statistics – Part 1
ORR (Objective Response Rate) and related statistics – Part 1

Durable Response Rate
Durable Response Rate

Efficacy - Overall Response Rate | Aliqopa US HCP
Efficacy - Overall Response Rate | Aliqopa US HCP

Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 | NEJM
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 | NEJM

COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate